TP53 and myelodysplastic syndrome: To date, no treatment has been clearly shown to be superior; however, in the ASCERTAIN trial, MDS patients with bi-allelic TP53 mutations treated with the oral hypomethylating agent decitabine/cedazuridine had a favorable survival of 13 months compared with historical outcomes [22].